The incidence of cervical intraepithelial neoplasia (CIN ... A large majority of high-grade lesions in the female genital tract emerge as monoclonal cell populations derived from the cervical ...

An investigational therapeutic vaccine showed clinical effectiveness in patients with human papillomavirus (HPV)16-positive ...

Among women ages 20 to 24 who were screened for cervical cancer from 2008 to 2022, rates of cervical intraepithelial ... rates of CIN3+ -- the precancerous lesions most likely to progress to ...

CIN: Cervical intraepithelial neoplasia ... Expression of E6/E7 oncogenes increases with the severity of the lesion. In cervical carcinoma the virus is integrated into the host cell chromosomes ...

Jan. 24, 2025 — A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according to the results from a phase II clinical ...

The Papanicolaou (Pap) smear is commonly used to screen for cervical cancer and since ... Administration to screen for high-grade cervical intraepithelial neoplasia. Women with positive test ...